Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, which targets demyelination and aims to protect or restore myelin integrity. The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated, supporting advancement into patient-focused studies.
In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The company believes the therapy may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. To support the program, the company is planning a partnership with Allucent and engaging neurological specialists.
LUCID-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The therapy is developed through Quantum BioPharma's wholly owned subsidiary, Lucid Psycheceuticals Inc.
Beyond its MS program, Quantum BioPharma is building a portfolio of innovative assets and biotech solutions for neurodegenerative and metabolic disorders and alcohol misuse disorders. The company invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 19.84% (as of March 31, 2026) of UWI at www.unbuzzd.com. The agreement with UWI includes royalty payments of 7% of sales from unbuzzd until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
The advancement of LUCID-MS into Phase 2 trials represents a significant step for patients with multiple sclerosis, a chronic condition that affects the central nervous system and can lead to disability. Current treatments primarily focus on immune modulation, but LUCID-MS aims to address the root cause of myelin loss. If successful, this therapy could provide a new option for patients who do not respond adequately to existing therapies.
For more information on Quantum BioPharma and its progress, visit the company's newsroom at https://ibn.fm/QNTM. The full article on this development is available at https://ibn.fm/AUhNl.
